Abstract: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.
Type:
Grant
Filed:
October 9, 2014
Date of Patent:
April 24, 2018
Assignee:
The Regents of the University of Colorado, a body corporate
Abstract: A method of treating a biological tissue that enables dry storage of said tissue is disclosed. In one embodiment, the method comprises contacting the biological tissue with a non-aqueous treatment solution comprising a polyhydric alcohol and a C1-C3 alcohol and removing a portion of the treatment solution from the solution-treated biological tissue. Also disclosed is biological tissue prepared using the above process and prosthetic devices made with such tissue.
Abstract: An automatic device for inoculating a sample on a substrate with a dilution mechanism formed by a head that holds a stylus in cooperation with a first dilution tank and a second dilution tank to dilute an original sample in at least one sub-sample and for inoculating the sub-sample on a substrate.
Abstract: The present invention relates to a method for stabilizing an enzyme by storing the enzyme in the presence of a stable coenzyme. The present invention further relates to an enzyme stabilized with a stable coenzyme, and to the use thereof in test elements for detecting analytes.
Type:
Grant
Filed:
August 19, 2010
Date of Patent:
February 20, 2018
Assignee:
ROCHE DIABETES CARE, INC.
Inventors:
Carina Horn, Dieter Heindl, Claudia Gaessler-Dietsche, Joachim Hoenes
Abstract: The present invention encompasses a glucose indicator protein, a biosensor comprising one or more glucose indicator proteins, and methods of use thereof.
Type:
Grant
Filed:
May 28, 2014
Date of Patent:
November 28, 2017
Assignee:
The Research Foundation for The State University of New York
Abstract: The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
Abstract: A method induces bacteria to enter into viable, but nonculturable state. The method includes subjecting a target bacterium to high pressure carbon dioxide treatment so as to make it enter into the viable, but nonculturable state, which can be demonstrated experimentally. The viable but nonculturable state can be entered quickly, such as within one hour.
Abstract: A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.
Abstract: The present invention relates to purification of butyrylcholinesterase using anion exchange material, where the butyrylcholinesterase content is enriched at least 10 fold per total protein in the composition.
Type:
Grant
Filed:
November 12, 2009
Date of Patent:
October 10, 2017
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Alexander Zaydenberg, Susan Weber, Patrick Gavit, Laura Lei, Wolfgang Teschner, Harald A. Butterweck, Ursula Mais-Paul, Hans-Peter Schwarz
Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.
Type:
Grant
Filed:
August 2, 2013
Date of Patent:
October 10, 2017
Assignee:
ELC Management LLC
Inventors:
Donald F. Collins, Daniel H. Maes, Neelam Muizzuddin
Abstract: A method of measuring a metabolic activity (MA) of a cell is provided. The method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of: (i) non-volatile soluble metabolic products; (ii) non-volatile soluble metabolic products and volatile soluble metabolic products; and (iii) volatile soluble metabolic products; wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell. Also provided are clinical methods which make use of the assay.
Type:
Grant
Filed:
May 18, 2014
Date of Patent:
October 10, 2017
Assignee:
Ramot at Tel-Aviv University Ltd.
Inventors:
Reuven Tirosh, Fernando Patolsky, Hagit Peretz-Soroka
Abstract: The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) antagonists with antithrombotic activity.
Abstract: Liquid stable enzyme compositions and methods of employing the same for cleaning, including warewashing and dishwashing, are disclosed. The stable enzyme compositions preferably employ an amphoteric surfactant stabilizing agent, such as disodium camphodiacetate (CADA), to stabilize a mixture of traditionally unstable enzymes, such as proteases and lipases.
Type:
Grant
Filed:
September 10, 2012
Date of Patent:
August 29, 2017
Assignee:
Ecolab USA Inc.
Inventors:
Clinton Hunt, Jr., Victor Fuk-Pong Man, Steven Eugene Lentsch, Lylien Tan, Yvonne Marie Killeen, Terrence P. Everson
Abstract: An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided.
Type:
Grant
Filed:
October 29, 2009
Date of Patent:
August 22, 2017
Assignee:
Yeda Research and Development Co. Ltd.
Inventors:
Yair Reisner, Eran Ophir, Yaki Eidelstein, Esther Bachar-Lustig
Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
Type:
Grant
Filed:
July 17, 2014
Date of Patent:
August 15, 2017
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
Abstract: The present invention provides methods for designing a filtration systems for capturing viable tumor cells, such as circulating tumor cells at high efficiency and high viability. The methods involve development of a set of “key engineering design parameters” that are crucial to achieve high tumor cell viability. These important design parameters include the filter geometry design, fluid delivery method, transfilter pressure and total filtration time.
Abstract: To provide an accelerated aging seed testing kit system, a single sheet of plastic or other suitable formable sheet material is pressed into the shape of a compartment base having recesses for mounting a seed holder. A seed holder that includes a seed support and a seed support holder is formed. The seed support holder is formed of a single sheet of plastic having radially extending tabs that fit into the recesses of the container to support the seed support above the bottom of the test kit. A bypass channel for addition of an aqueous solution used in the prescribed test condition is provided in the seed holder. A lid is formed out of one piece of plastic having a bendable tab to serve as a port and the openings and connecting points of the lid and seed holder are positioned so they can only fit together in one orientation having the port above the bypass channel. The saturated cold germination test kit includes a compartment base, a lid and a holder for an oxygen scavenger.
Type:
Grant
Filed:
March 2, 2015
Date of Patent:
July 11, 2017
Assignee:
Kamterter Products, LLC
Inventors:
Christopher Lee Petersen, John Alvin Eastin, Timothy Raymond Meyer
Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.
Type:
Grant
Filed:
November 14, 2013
Date of Patent:
June 27, 2017
Assignee:
ELC Management LLC
Inventors:
Donald F. Collins, Daniel H. Maes, Neelam Muizzuddin